

Tables

HPV type	HPV baseline	Cases of CIN3+	PPV CIN3+ % (95% CI)
Negative	379	41	10.8 (8.0-14.5)
6	23	2	8.7 (1.5-29.5)
11	17	1	5.9 (0.3-30.8)
16	148	72	48.6 (40.4-57.0)
18	15	3	20.0 (5.3-48.6)
31	27	10	37.0 (20.1-57.3)
33	33	19	57.6 (39.4-74.1)
Total	642	148	23.1 (19.9-26.5)

Table S1: HPV genotypes at baseline, cases of CIN3+ and PPV CIN3+ during follow-up. PPV = positive predictive value




Figure S1: HPV status at baseline by age.




Figure S2: Cases of CIN3+ during follow-up by age.




Figure S3: Cumulative incidence of CIN3+ by years of follow-up comparing HPV 16/33, HPV 18/31 and HPV negative.




Figure S4: Cumulative incidence of CIN3+ by years of follow-up comparing HPV 16/33, HPV 18/31 and HPV negative, with 95% CI.




Figure S5: Cumulative incidence of CIN3+ using four years quarantine from baseline, comparing women with HPV 16/33, HPV 18/31 and HPV negative.




Figure S6: Cumulative incidence of CIN3+ by years of follow up using four years quarantine from baseline, comparing HPV 16/33, HPV 18/31 and HPV negative, with 95% CI.




Figure S7: Cumulative incidence of CIN3+ by years of follow-up comparing women with a positive HPV test and a negative HPV test at baseline, with 95% CI.




Figure S8: Cumulative incidence of CIN3+ by years of follow-up comparing women with HPV 31/33, HPV 16/18 and HPV negative, with 95% CI.




Figure S9: Cumulative incidence of CIN3+ by years of follow-up using four years quarantine from baseline, comparing women with a positive HPV test and women with a negative HPV test, with 95% CI.




Figure S10: Cumulative incidence of CIN3+ by years of follow-up using four years quarantine from baseline, comparing women with HPV 16/18, HPV 31/33 and women with a negative HPV test, with 95% CI.




Figure S11: Cumulative incidence of CIN3+ by years of follow-up comparing all HPV genotypes.




Figure S12: Cumulative incidence of CIN3+ by years of follow-up using four years quarantine from baseline, comparing all HPV genotypes.